Press Release

Ophthotech to Present at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell & Gene Therapy Investor Day

NEW YORK--(BUSINESS WIRE)--Mar. 14, 2019-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell and Gene Therapy Investor Day in New York, NY, on Thursday, March 21, 2019 at 2:15 p.m. Eastern Time.

A live video webcast of Dr. Rezaei’s presentation will be available at: http://www.arminvestorday.com/webcast. An archived replay of the webcast will be available on the Company’s website at www.ophthotech.com for 14 days after the conference.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of transformative gene therapies and novel therapeutics to treat retinal diseases, with a focus on orphan and age related indications. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

 

Source: Ophthotech Corporation

Investors:
Ophthotech Corporation
Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
kathy.galante@ophthotech.com
or
Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com